IP Verse

Propane-I-Sulfonic Acid {3- [5- (4- Chloro-Phenyl) -1H-Pyrrolo [2, 3-B} Pyridine-3-Carbonyl] -2, 4-Difluoro-Phenyl} -Amide Compositions And Uses Thereof - EP2955180

The patent EP2955180 was granted to F Hoffmann LA Roche on Jan 10, 2018. The application was originally filed on Mar 31, 2010 under application number EP15171526A. The patent is currently recorded with a legal status of "Revoked".

EP2955180

F HOFFMANN LA ROCHE
Application Number
EP15171526A
Filing Date
Mar 31, 2010
Status
Revoked
Feb 6, 2024
Grant Date
Jan 10, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKOct 5, 2018ELKINGTON AND FIFEADMISSIBLE

Patent Citations (5) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2004077595
DESCRIPTIONUS6350786
DESCRIPTIONWO2007002325
OPPOSITIONWO2007002325
SEARCHWO2007002325

Non-Patent Literature (NPL) Citations (24) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- BAGSHAWE, DRUG DEV. RES., (1995), vol. 34, pages 220 - 230-
DESCRIPTION- BALAK, CLIN CANCER RES., (2006), vol. 12, pages 6494 - 501-
DESCRIPTION- BERTOLINI ET AL., J. MED. CHEM., (1997), vol. 40, pages 2011 - 2016-
DESCRIPTION- CRUMP, CURR PHARM DES, (2002), vol. 8, no. 25, pages 2243 - 8-
DESCRIPTION- HOOD, J.D. ET AL., SCIENCE, (2002), vol. 296, page 2404-
DESCRIPTION- KUNNIMALAIYAAN ET AL., ANTICANCER DRUGS, (2006), vol. 17, no. 2, pages 139 - 42-
DESCRIPTION- MATSUMORO; ZOGRAFI, PHARMACEUTICAL RESEARCH, (1999), vol. 16, no. 11, pages 1722 - 1728-
DESCRIPTION- M.G. VACHON ET AL., J. MICROENCAPSULATION, (1997), vol. 14, pages 281 - 301-
DESCRIPTION- NIIHORI ET AL., NAT GENET., (2006), vol. 38, no. 3, pages 294 - 6-
DESCRIPTION- Remington's Pharmaceutical Sciences, 19th edition, MACK PUBLISHING CO., (1995), vol. 2, page 1457-
DESCRIPTION- SHAN ET AL., J PH ARM SCI, (1997), vol. 86, no. 7, pages 756 - 757-
DESCRIPTION- VANDELLI ET AL., J. MICROENCAPSULATION, (1993), vol. 10, pages 55 - 65-
OPPOSITION- anonymous, "Assessment report: Zelboraf", European Medicines Agency (Sciences Medicines Health), London, (20111215), pages 1 - 103, XP055585594-
OPPOSITION- Anonymous, "Australian Public Assessment Report for Vemurafebib", TGA - Health Safety Regulation, (20120000), pages 1 - 96, XP055585606-
OPPOSITION- anonymous, "Safety Study of PLX4032 in Patients With Solid Tumors", clinicaltrial.gov NCT00405587, (20061130), pages 1 - 12, URL: www.clinicaltrial.gov, XP055585583-
OPPOSITION- "Assessment report: Zelboraf", European Medicines Agency (Sciences Medicines Health), London, (20111215), pages 1 - 103, XP055585594-
OPPOSITION- Australian Public Assessment Report for Vemurafebib, TGA - Health Safety Regulation, (20120000), pages 1 - 96, XP055585606-
OPPOSITION- "Safety Study of PLX4032 in Patients With Solid Tumors", clinicaltrial.gov NCT00405587, (20063011), pages 1 - 12, XP055585583-
OPPOSITION- CAIRA, "Crystalline Polymorphism of Organic Compounds", Topics in Current Chemistry, Berlin, (19980000), vol. 198, pages 163 - 208, XP008166276
OPPOSITION- S BYRN et al., "Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations", Pharmaceutical Research, (19950700), vol. 12, no. 7, pages 945 - 954, XP000996386
OPPOSITION- THRELFALL, "Analysis of Organic Polymorphs - A Review", ANALYST, (20051000), vol. 120, pages 2435 - 2460, XP009026967
OPPOSITION- K. T. FLAHERTY et al., "Inhibition of Mutated, Activated BRAF in Metastatic Melanoma", N Engl J Med, (20100000), vol. 363, doi:doi:10.1056/NEJMoa1002011, pages 809 - 819, XP009183149
OPPOSITION- K. T. FLAHERTY et al., "Inhibition of Mutated, Activated BRAF in Metastatic Melanoma", The New England Journal of Medicine, - NEJM -, (20100000), vol. 363, pages 809 - 819, XP009183149
SEARCH- CAIRA, "Crystalline Polymorphism of Organic Compounds", TOPICS IN CURRENT CHEMISTRY, SPRINGER, BERLIN, DE, (19980101), vol. 198, ISSN 0340-1022, pages 163 - 208, XP008166276 [Y] 1-9 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents